anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide an antiulcer agent containing 1-substituted-3-(2-norbornyl) urea as an active component, having anticholine activity and autonomic nerve suppressing action, free from the central nerve suppressing action as side effect, and useful especially to peptic ulcer caused by stress. CONSTITUTION:The compound of formula (X is O or S; R1 is H or 1-6C alkyl; R2 is 1-6C alkyl or phenyl; when R2 is phenyl, R1 is H) is used as an active component of the objective antiulcer agent. It has been found that the compound of formula is effective to various ulcers as an antiulcer agent, especially as a remedy for peptic ulcer caused by stress. Furthermore, the compound of formula has anticoline activity and autonomic nerve supressing action, and excellent effect to improve the microcirculation. It has little side effect to suppress the central nervous system. The antiulcer agent is administered orally or by intravenous injection. Dose: preferably 1-200mg/kg by oral administration and 0.5-10mg/kg by intravenous injection.
OBJECTIVES: Quantitative sensory testing (QST) has been used for decades to study sensory abnormalities in multiple conditions in which the somatosensory system is compromised, including pain. It is commonly used in pharmacologic studies on chronic pain but less so in conjunction with neuromodulation. This review aims to assess the utility of QST in spinal cord stimulation (SCS) protocols.
MATERIALS AND METHODS: For this narrative review, we searched PubMed for records of studies in which sensory testing has been performed as part of a clinical study on SCS from 1975 onward until October 2023. We focused on studies in which QST has been used to explore the effect of SCS on neuropathic, neuropathic-like, or mixed pain.
RESULTS: Our search identified 22 useful studies, all small and exploratory, using heterogeneous methods. Four studies used the full battery of validated German Research Network on Neuropathic Pain QST. There is emerging evidence that assessment dynamic mechanical allodynia (eight studies), and mechanical/thermal temporal summation of pain (eight studies) may have a role in quantifying the response to various SCS waveforms. There also were sporadic reports of improvement of sensory deficits in a proportion of patients with neuropathic pain that warrant further study.
CONCLUSIONS: We recommend the adoption of QST into future clinical research protocols, using either the full QST protocol or a less time-demanding short-form QST.
AD16 placebo tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose. Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 placebo From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 placebo tablets was nine days.
FIELD: medicine, pharmacology. SUBSTANCE: preparation has an inhibitor of Ca ++ -activated endopeptidases - antipain and lupeptin at ratio to morphine 1: 20. Its analgetic effect exceeds that of morphine but tolerance and physical dependence are much weaker as compared with morphine. Also, addition of inhibitors of Ca ++ -activated endopeptidases to morphine solution decreases positive-fortifying properties of the latter sharply. So, this preparation is an effective agent for analgesia and it can be used at low doses, for example, in oncology for arresting the strong lasting pain syndromes. EFFECT: enhanced analgetic action, decreased dependence and tolerance. 3 cl, 5 dwg
Participants in Part 3 will receive 3 days of once daily repeat dosing of GSK4381406 in Treatment Period 1 followed by placebo in Treatment Period 2, or placebo in Treatment Period 1 and GSK4381406 in Treatment Period 2 in a cross-over design with a washout period of at least 14 days between each dosing period. Participants will be dosed in fasted state. The participants will be challenged with indomethacin during the final 2 days of each dosing period.
Participants were randomized to receive Armour Thyroid at a dose corresponding to their pre-randomized dose of synthetic T4. During the first 18 to 36 weeks (titration period) the dose of Armour Thyroid could be titrated based on levels of thyroid stimulating hormone (TSH), in order to achieve TSH levels within the normal reference range (0.45 - 4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of Armour Thyroid for an additional 12 weeks (stabilization period).
Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
Oxygen-sensing materials and methods are disclosed. The materials include oxygen-sensing chromophores embedded in a solid matrix including silk fibroin in an amount by weight of at least 50% of the total weight of the solid matrix. The solid matrix possesses at least partial transparency at relevant wavelengths. The solid matrix is biocompatible and biodegradable. The solid matrix is not a hydrogel. The chromophores are distributed throughout the solid matrix. Tissue oxygenation can be estimated from phosphorescence measurements made from oxygen-sensing materials implanted in subject.
UNLABELLED: Efflux pumps and biofilm play significant roles in bacterial antibiotic resistance. This study investigates the potential of chlorogenic acid (CGA) and carnosol (CL), as phenolic and diterpene compounds, respectively, for their inhibitory effects on efflux pumps. Among the 12 multidrug-resistant (MDR) strains of Staphylococcus aureus and Pseudomonas aeruginosa isolated from nosocomial skin infections, eight strains were identified as extensively drug resistant (XDR) using the disc diffusion method. The presence of efflux pumps in MDR strains of S. aureus and P. aeruginosa was screened using carbonyl cyanide-m-chlorophenylhydrazone. Between the 12 MDR strains of S. aureus and P. aeruginosa, 80% (4 out of 5) of the S. aureus strains and 85.7% (6 out of 7) of the P. aeruginosa strains exhibited active efflux pumps associated with gentamicin resistance. The checkerboard assay results, in combination with gentamicin, demonstrated that CGA exhibited a reduction in the minimum inhibitory concentration (MIC) for XDR S. aureus strain. Similarly, CL showed a synergistic effect and reduced the MIC for both XDR strains of S. aureus and P. aeruginosa. Flow cytometry was used to examine efflux pump activity at sub-MIC concentrations of 1/8, 1/4, and 1/2 MIC in comparison to the control. In XDR S. aureus, CGA demonstrated 39%, 70%, and 19% inhibition, while CL exhibited 74%, 73.5%, and 62% suppression. In XDR P. aeruginosa, CL exhibited inhibition rates of 25%, 10%, and 15%. The inhibition of biofilm formation was assessed using the microtiter plate method, resulting in successful inhibition of biofilm formation. Finally, the MTT assay was conducted, and it confirmed minimal cytotoxicity. Given the significant reduction in efflux pump activity and biofilm formation observed with CGA and CL in this study, these compounds can be considered as potential inhibitors of efflux pumps and biofilm formation, offering potential strategies to overcome antimicrobial resistance.
IMPORTANCE: In summary, CGA and CL demonstrated promising potentiating antimicrobial effects against XDR strains of Staphylococcus aureus and Pseudomonas aeruginosa, suggesting their probably potential as candidates for addressing nosocomial pathogens. They exhibited significant suppression of efflux pump activity, indicating a possible successful inhibition of this mechanism. Moreover, all substances effectively inhibited biofilm formation, while showing minimal cytotoxicity. However, further advancement to clinical trials is needed to evaluate the feasibility of utilizing CGA and CL for reversing bacterial XDR efflux and determining their efficacy against biofilms. These trials will provide valuable insights into the practical applications of these compounds in combating drug-resistant infections.
Ageing is characterised by a gradual loss of physical and functional integrity, which progressively affects the health of the body. A particular feature of ageing is the increase in the number of senescent cells that have entered into a state of the irreversible cell cycle arrest after exceeding an inherent or environmental stress level. Although cellular senescence is essential for various physiological processes, it plays a detrimental role in a large number of age-related diseases. A first aspect of the invention provides a composition of plant extracts for reducing the effects of ageing, which comprises: at least 6.0 wt% asiaticosides, preferably from a Centella asiatica extract; at least 2.5 wt% verbascosides, preferably from a cistanche extract; at least 12.5 wt% hesperidin, preferably from a sweet orange extract; and at least 3.0 wt% punicalagins, preferably from a pomegranate extract. A composition like that described prevents the negative effects of ageing by reducing the number of cells that reach the state of senescence, owing to the ability of the formulation to prevent or reduce telomer shortening during cell division. This composition is particularly suitable for preventing the effects of skin ageing.
Stylocarotid artery syndrome (SAS) is a rare variant of Eagle's syndrome that may lead to transient ischemic attack or stroke. The underlying pathophysiological mechanism involves compression of the internal carotid artery by an elongated styloid process (ESP), potentially resulting in vascular occlusion or dissection. An ESP exceeding 2.5 cm is deemed elongated, with a length of 3.0 cm considered clinically significant. Although the prevalence of ESP ranges from 4.0% to 7.3%, symptomatic cases are rare; symptoms are present in only approximately 4.0% of individuals with an ESP. Unlike the typical symptoms of Eagle's syndrome, SAS may not cause pharyngeal discomfort, the sensation of a foreign body in the throat, dysphagia, or facial pain. This absence of characteristic symptoms as well as the development of central nervous system symptoms often leads patients to seek care from neurologists instead of otolaryngologists, increasing the likelihood of misdiagnosis or underdiagnosis. We herein report a unique case of ischemic stroke caused by SAS and present a literature review on cases of SAS-associated ischemic stroke published in the past decade. The reporting of this study conforms to the CARE guidelines.
Cognitive impairment (CI) and memory deficit are prevalent manifestations of multiple sclerosis (MS). This study explores the therapeutic potential of arbutin on memory deficits using a rat hippocampal demyelination model induced by lysophosphatidylcholine (LPC). Demyelination was induced by bilateral injection of 1% LPC into the CA1 area of the hippocampus, and the treated group received daily arbutin injections (50 mg/kg, i.p) for two weeks. Arbutin significantly improved memory impairment 14 days post-demyelination as assessed by Morris water maze test. Histological and immunohistochemical analyses demonstrated that arbutin reduced demyelination suppressed pro-inflammatory markers (IL-1β, TNF-α) and increased anti-inflammatory cytokine IL-10. Arbutin also diminished astrocyte activation, decreased iNOS, enhanced anti-oxidative factors (Nrf2, HO-1), and exhibited neuroprotective effects by elevating myelin markers (MBP) and brain derived neurotrophic factor (BDNF). These findings propose arbutin as a potential therapeutic candidate for multiple sclerosis-associated memory deficits, warranting further clinical exploration.
It is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand.
PURPOSE: An Ulmus davidiana var. japonica extract is provided to use a supernatant as an effective pharmaceutical ingredient in an ointment and a bandage and to treat wound or pressure sore. CONSTITUTION: A method for manufacturing an Ulmus davidiana var. japonica extract for treating skin comprises the steps of: pulverizing Ulmus davidiana var. japonica in a size of 0.3-3 micrometers; dissolving the Ulmus davidiana var. japonica powder in water and centrifuging; and obtaining a supernatant as a treatment material. A method for manufacturing a band for treating skin comprises the steps of: absorbing the extract onto a pad; and drying the pad. [Reference numerals] (AA) Pulverize Ulmus davidiana var. japonica; (BB) Ulmus davidiana var. japonica powder/dissolve and centrifuge; (CC) Separate a supernatant
A process for making foamed glasses and ceramics from sol-gels is disclosed. The method includes preparing a mixture of reactants capable of forming a sol-gel with addition of a catalyst to control the condensation stage followed by foaming using vigorous agitation in the presence of surfactants. The gelled bodies are aged, dried, and thermally stabilized to obtain a consolidated macroporous material. The resulting structure comprises a three-dimensional network of spherical open pores that are thoroughly interconnected. The process may involve sol-gel systems using a mixture of metal alkoxides, and may produce glasses in unary systems (SiO 2 ), binary systems (70% mol SiO 2 -30% mol CaO), and ternary systems (60% mol SiO 2 , 36% mol CaO, 4% mol P 2 O 5 ). The macro-porous material has pores in the 10-500 μm range and has potential for use as matrix in tissue engineering, in bone repair, and in organ regeneration.
JRA is the most common chronic inflammatory pediatric rheumatic disease. JRA may be related to a complex genetic trait. It is rare to have two or more affected siblings, or sibpairs, within one family. The JRA ASP (Affected Sibpair) Registry is a nationwide effort and will collect information and blood samples from JRA sibpairs and their families. Unaffected family members (e.g., mother, father, and unaffected children) are also invited to participate.

Patients and their families may enroll in the registry in one of two ways: patients may contact the registry directly, or they may be referred to the registry through their physician. Once the family has qualified to join the registry, the family will be asked to complete a questionnaire on the medical history of their JRA-affected members. Physicians of the JRA-affected members will be asked to complete questionnaires about their patients' conditions. Family members will also be invited to provide a one-time blood sample. Information collected through the registry will help researchers identify genes involved in JRA susceptibility.
The antihypertensive effects of PRESTALIA have been demonstrated in two randomized controlled trials.

The highest strength of PRESTALIA (14/10 mg) was studied in a double-blind, active controlled study in hypertensive patients. A total of 837 patients with seated diastolic pressure 95 to 115 mmHg (mean baseline systolic/diastolic blood pressure was 158/101 mmHg) received treatments of PRESTALIA 14/10 mg, perindopril erbumine 16 mg, or amlodipine 10 mg once daily for 6 weeks. The mean age of the population was 51 years, 51% of patients were male, and 34% were black. Overall, 20% of the population had type 2 diabetes.

At Week 6, PRESTALIA 14/10 mg produced statistically significantly greater reductions in blood pressure than each of the monotherapies. The reductions in systolic/diastolic blood pressure with PRESTALIA 14/10 mg were 10.1/6.3 mmHg greater than with perindopril erbumine 16 mg and 3.9/2.5 mmHg greater than with amlodipine 10 mg. In black patients and in diabetic patients, treatment with PRESTALIA 14/10 mg did not provide additional antihypertensive effect beyond that achieved with use of amlodipine 10 mg.

The lowest strength of perindopril arginine/amlodipine (3.5/2.5 mg) was studied in 246 hypertensive patients. A total of 1581 patients with supine diastolic pressure 95-110 mmHg (mean baseline systolic/diastolic blood pressure was 161/101 mmHg) received treatment with perindopril arginine/amlodipine 3.5/2.5 mg, perindopril arginine 3.5 mg, perindopril arginine 5 mg, amlodipine 2.5 mg, amlodipine 5 mg, or placebo. The mean age of the population was 52 years, 47% were male, and 1% were black. No included patients had a history of diabetes.

At Week 8, PRESTALIA 3.5/2.5 mg produced statistically significantly greater reductions in blood pressure than perindopril arginine 3.5 mg and amlodipine 2.5 mg. The reduction in systolic/diastolic blood pressure with perindopril arginine/amlodipine 3.5/2.5 mg was 7.2/4.1 mmHg greater than with placebo.
PURPOSE:To recover capsules preventing the damage of the capsule in the form dispersed in a desired liquid, by carrying out liquid-liquid gelation reaction to form a reaction mixture liquid containing capsules and replacing the reaction mixture liquid with the desired liquid to be used as a core liquid of the capsule. CONSTITUTION:A core liquid forming the core part of a capsule is poured into a dripping tank 1 through an inlet 5 and a solution to be reacted and gelled with the core liquid is charged into a reaction tank 2. The core liquid is dripped through nozzles 3 into the reaction liquid in the reaction chamber 2. When the encapsulation is finished, a desired liquid is introduced into the tank by opening a valve 15 of a liquid introducing pipe 12. The liquid above a definite level in the reaction tank is overflowed through a mesh 11. When the reaction mixture liquid is essentially replaced with the introduced liquid, the valve 15 is closed and a valve 16 is opened to recover the capsule together with the liquid.
The invention relates to a novel oral solid medicinal composition and its preparation method. The medicinal composition is made from medicinal active components of S-amlodipine besylate and metoprolol or its pharmaceutical salt, and pharmaceutically acceptable auxiliary materials of a hydrophobic retarding agent, a gel-type retarding agent and a filler. According to the invention, hydrophobic retarding agent and metoprolol are dissolved or fused together as an adhesive, and the adhesive is then mixed with the gel-type retarding agent for granulation and tabletting, so as to reach a 12-hour slow release effect. The medicine provided by the invention is used for treating primary hypertension. S-amlodipine besylate and metoprolol have great synergism. The medicinal composition can be used to enhance the effect of pressure reduction or simultaneously eliminate adverse effects caused by respective medicines, and has little medicinal side-effect, long controlled release time and good stability. In vitro release rate of the medicinal composition will not change if it stored for a long time. Therefore, the medicinal composition is especially applicable to be taken by old patients for a long time.
The surface of the skin is continually exposed to pro-inflammatory stimuli; however, it is unclear why it is not constantly inflamed due to this exposure. Here, we showed undifferentiated keratinocytes residing in the deep epidermis could trigger a strong inflammatory response due to their high expression of pattern recognition receptors (PRRs) that detect damage or pathogens. As keratinocytes differentiated, they migrated outward toward the surface of the skin and decreased their PRR expression, which led to dampened immune responses. ZNF750, a transcription factor expressed only in differentiated keratinocytes, recruited the histone demethylase KDM1A/LSD1 to silence genes coding for PRRs (TLR3, IFIH1/MDA5, and DDX58/RIG1). Loss of ZNF750 or KDM1A in human keratinocytes or mice resulted in sustained and excessive inflammation resembling psoriatic skin, which could be restored to homeostatic conditions upon silencing of TLR3. Our findings explain how the skin's surface prevents excessive inflammation through ZNF750- and KDM1A-mediated suppression of PRRs.
PURPOSE OF REVIEW: Crohn's disease is a relapsing inflammatory condition and disease recurrence after surgery is common. Significant variation in clinical practice remains despite progress in management of postoperative Crohn's disease. In this review, we summarise current management strategies and guidelines, unmet needs, and research progress in this field.
RECENT FINDINGS: There has been real progress in risk stratifying individuals' postsurgery and tailoring therapies based on their risk; this has been incorporated into current management guidelines in the USA, UK, and Europe. Furthermore, novel noninvasive monitoring tools such as intestinal ultrasound have shown high sensitivity and specificity at detecting disease recurrence and are an attractive point-of-care test. Recent studies are also investigating multiomic biomarkers to prognosticate postoperative Crohn's disease. However, given the heterogeneity within this condition, large multicentre clinical validation across all age groups is needed for clinical translation in the future.
SUMMARY: Ongoing progress in research and the development of novel prognostic and noninvasive disease monitoring tools offers hope for personalised therapy tailored to individual recurrence risk in postoperative Crohn's disease.
PURPOSE OF REVIEW: There are high rates of sexually transmitted infections (STIs) worldwide. Adolescents and young adults (AYA) ages 15-24 years remain one of the populations that is most vulnerable to STIs. The goal of this review is to summarize recent international updates in adolescent STI screening and treatment.
RECENT FINDINGS: Normalizing sexual history taking and STI testing, and advocating for adolescents to receive comprehensive sexuality education improves stigma surrounding sexual health. The global rise in syphilis is pervasive and includes high rates of infection among AYA and women of reproductive age - universal screening may be indicated depending on local epidemiology. Gonococcal antimicrobial resistance remains a significant public health concern worldwide, thus judicious use of antimicrobials and reporting cases of resistance is crucial. Sexual health services are increasingly using virtual platforms, which may be an effective strategy for STI testing and treatment among AYA.
SUMMARY: Specific areas of focus to address the STI epidemic among AYA include reducing stigma surrounding sexual health, screening, and treatment of STIs, especially with the global rise in syphilis and high rates of gonorrhea resistance, in addition to increased use of telehealth services as effective education and intervention strategies.